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Abstract The objective of this study was to estimate the prev-
alence of metabolic syndrome and its individual components
in South Asia region. A search was conducted on PubMed,
Scopus and OvidSP (MedLine and EMBASE) using the term
‘metabolic syndrome’, ‘prevalence’ and the name of each
South Asian country for studies published on or after the year
2000. Reference lists and citation references of the included
papers were also checked. Eligibility criteria were mainly
population-based studies on both gender and healthy partici-
pants aged ≥18 years. Four definitions of metabolic syndrome
were considered: theWorld Health Organisation (1999), Third
Adult Treatment Panel (2001) and its modified version (2005)
and International Diabetes Federation (2005). A total of 558
papers were retrieved from all sources, of which 16 relevant
studies were identified comprising 14,515 males (44.1 %) and
18,390 females (55.9 %). The weighted mean prevalence of
metabolic syndrome was 14.0 % (WHO), 26.1 % (ATPIII),
29.8 % (IDF) and 32.5 % (modified ATPIII). Low levels of
HDL cholesterol and hypertension were prevalent in half of
the study population. Overall, females had a higher prevalence
of MS under all definitions except WHO. Females were more
likely to have low levels of HDL cholesterol (68.8 vs 37.9 %)
and central obesity (47.9 vs 37.9 %), whereas males were
comparatively more hypertensive (42.3 vs 38.1 %). Despite
the high rates of metabolic risk factors, research is extremely
sparse in South Asia preventing knowledge of actual burden.
Along with the increased access to clinical intervention, pre-
vention strategies should be intensified with special attention
to females.
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Introduction
Metabolic syndrome (MS) refers to the constellation of risk
factors related to cardiovascular disease (CVD) and diabetes.
MS represents the clustering of mainly hyperglycaemia, hy-
pertension, dyslipidemia and central obesity. These metabolic
factors are co-occurring, inter-related and commonly share
underlying causes, features and mechanisms [1]. Patients with
MS are at two-fold risk of developing CVD over a period of 5
to 10 years and at five-fold risk of having type 2 diabetes
compared to individuals withoutMS [2]. Themajor advantage
of MS is not to function as a risk assessment tool, but rather to
identify patients with a shared pathophysiology who are at
high risk of developing CVD and diabetes [3]. MS also helps
to induce and intensify lifestyle changes in clinical practice
[4].
The prevalence of MS is high worldwide—35 % in the
USA [5], 24.9 % in Latin America [6] and in the range be-
tween 20.7 and 37.2 % in the Gulf countries [7] under the
Adult Treatment Panel (ATP III) criteria. South Asia is home
to nearly one fourth of the world population and has the
highest absolute burden of CVD in the world [8]. Also,
CVD mortality rates in this region are higher than those in
Western and East Asian countries [9]. The Global INTE
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RHEART study reported that CVD prevails at a younger age
in South Asians than in any other population [10].
The burden of CVD and its risk factors are escalating
alarmingly in South Asia. For example, the global burden of
disease has projected that India alone will have the highest
number of individuals with CVD than in any other region by
the year 2020 [11]. Likewise, the prevalence of MS compo-
nents such as obesity, hypertension, dyslipidemia, along with
lifestyle factors such as smoking is increasingly high in this
region [9].
With this backdrop, the aims of this systematic review are
to identify robust epidemiological evidence of MS in the
South Asia region and to estimate the prevalence of MS and
its individual components.
Methods
Inclusion and exclusion criteria
The main inclusion criterion was English language full text
articles published on or after the year 2000 to July 2013. Like-
wise, only population-based studies on apparently healthy sub-
jects aged ≥18 years, consisting both genders and sample size
of more than 500, were included. Studies on patients, targeted
to particular occupational groups, conducted in hospital set-
tings and among South Asian immigrants were excluded.
Search and selection methods
The search yielded a total number of 558 papers: 369 from
PubMed, 133 from Scopus, 49 from OvidSP (MedLine/
EMBASE) and 7 from reference search. A search was con-
ducted in three major biomedical databases: PubMed, OvidSP
(MedLine and EMBASE) and Scopus. The search terms
‘prevalence’ and ‘metabolic syndrome’ were combined with
the name of each South Asian country: Afghanistan, Bangla-
desh, Bhutan, India, Maldives, Nepal, Pakistan and Sri Lanka.
Studies were searched by titles and/or abstracts. Other search
terms for ‘metabolic syndrome’—‘metabolic syndrome X’,
‘syndrome X’, ‘insulin resistance syndrome X’, ‘Reaven Syn-
drome X’—were also considered. In addition, reference lists
were also scrutinized to find relevant published articles.
Study characteristics
This systematic review examined a total of 16 studies com-
prising 14,515 males (44.1 %) and 18,390 females (55.9 %).
Ten studies were conducted in India [12–21], two each in Sri
Lanka [22, 23] and Bangladesh [24, 25] and one each in Pa-
kistan [26] and Nepal [27]. Eight studies were carried out in
urban settings [12–15, 18, 19, 21, 22], three in rural [24–26],
four in both urban and rural [16, 17, 20, 23], and one study did
not mention setting [27]. No single study was found from
Maldives, Bhutan or Afghanistan. Fifteen included studies
that were cross-sectional and one was longitudinal. Ten stud-
ies mentioned the study year, out of which six were conducted
between 2005 and 2010. Three studies had a participant range
of 500–1000, nine had between 500 and 2500 participants and
four studies had more than 2500 participants.
Thirteen studies selected study participants by randomized
sampling method, whereas in two studies [21, 27], they were
selected non-randomly. The response rate of the participants
varied from 61.3 to 98.2 %.
The detailed summary of the included studies is presented
in the supplementary material 2.
Data extraction and quality appraisal
A data extraction form was developed using the Centre for
Reviews and Dissemination guidance template [28]. The data
form recorded basic information (authors, study year, title of
paper, journal details), detailed information of each short-
listed article (study design, study location, study objectives,
study population, sample size, key findings), and finally the
reviewers comments. The accuracy of the extracted data was
double checked, and amendments were made. The quality of
the studies was assessed using the Critical Appraisal Skill
Program (CASP) checklist for systematic reviews [29].
The flow diagram of article selection process is shown in
Fig. 1.
Definitions
This study considered the four key definitions of MS: the
World Health Organisation (WHO, 1999) [30], the National
Titles / abstracts excluded
(n = 505)
- Not meeting inclusion criteria        
- Not original research
- Duplicates across the databases
Total articles retrieved 
from the databases        
(n = 558)
Articles selected for full   
text  review  (n = 53)
Articles excluded   (n = 36)
- Not meeting inclusion criteria        
- Full text not available
- Same data used for several 
studies
- MS criteria other than ATPIII, 
modified ATP III, WHO, and IDF
Final articles included  (n=16)
(India 10, Sri Lanka 2, Bangladesh 
2, Pakistan 1, Nepal 1, Afghanistan 
0, Bhutan 0, Maldives 0)
Fig. 1 Flow diagram for selection of the articles
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Cholesterol Education Program-Adult Treatment Panel III
(NCEP-ATPIII,2001) [31], and its modified version 2005
[32], and the definition defined by the International Diabetes
Federation (IDF, 2005) [33]. These definitions mostly
consisted of fasting glucose, blood pressure, triglycerides,
high-density lipoprotein cholesterol (HDL) and obesity as
components. However, these definitions vary in cut-off points
and have differences in the terms of prioritizing certain com-
ponents. Details of these definitions are presented in the sup-
plementary material 1.
Use of MS definitions
Four studies used ATP III definition only [14, 15, 20, 25],
three studies considered modified ATP III definition only
[13, 18, 21] and one study used IDF definition only [23].
Likewise, three studies followed ATP III and IDF definitions
[16, 26, 27], one study followed modified ATP III and IDF
definitions [22] and one study considered ATP III and modi-
fied ATP III definitions [17]. Further, one study each used
WHO, ATP III and IDF definitions [12]; WHO, modified
ATP III and IDF definitions [24]; and ATP III, modified
ATPIII and IDF definitions [19].
We calculated mean prevalence (weighted) of MS and its
individual components as follows: sum of number of cases in
all or relevant studies/sum of number of participants in all or
relevant studies×100. In a few studies, prevalence data were
available only in certain categories, mainly by gender, urban
and rural setting and ethnicity. In such cases, we calculated the
overall prevalence by combining the existing data. The sex
standardized mean prevalence of MS was calculated consid-
ering total study participants as a standard population.
Results
Prevalence of metabolic syndrome
The mean prevalence ofMS (weighted) was 26.1 % (ATP III),
29.8 % (IDF), 32.5 % (modified ATP III) and 14.0 % (WHO).
By any definitions, the prevalence ranged from 8.6 to 46.1 %.
The sex standardized mean prevalence of MS was 25.4 %
(ATPIII), 28.8 % (IDF), 36.2 % (modified ATPIII) and
13.9 % (WHO). The weighted mean prevalence of MS and
its individual components are shown in Table 1.
The prevalence of MS was highly reported in the Punjabi
community in India (35.8 %) [19] by ATP III criteria; in rural
area of Pakistan (40.0 %) [26] by IDF criteria; in Colombo, Sri
Lanka (46.1 %) [22] by modified ATP III criteria; and in
Chennai city, India (23.2 %) [12] by WHO criteria.
The weighted mean prevalence of MS was higher in fe-
males than that in males [ATP: 29.5 vs 22.1 %; IDF: 34.3 vs
18.8 %; modified ATP III: 35.8 vs 28.8 %], except when
considering the WHO definition (12.8 vs 15.6 %). The gender
difference in the prevalence of MS was more pronounced in
rural areas of Pakistan [26] where the difference in the preva-
lence was 37 % by the IDF criteria (males, 13 %; females,
50 %) and 20 % by ATP III criteria (males, 20 %; females,
40 %). However, examining the studies individually, only one
study under ATP III criteria [15], none of the studies under
IDF criteria, three studies under modified ATP III criteria [13,
17, 21], and one study under WHO criteria [12] reported
higher prevalence in males. The prevalence of MS was found
nearly two-fold higher in males than in females in a study
carried out in Mumbai city, India [21].
Seven studies [14, 15, 17–19, 22, 23] reported age-adjusted
prevalence, of which four [14, 18, 19, 23] studies compared it
with crude prevalence. Age-adjusted prevalence was lower in
all of the studies.
Nine studies provided prevalence of MS by age group.
In eight studies [14, 15, 18, 19, 22–24, 27], the preva-
lence was observed to be increased with the increment in
age, and it was highest in the age group above 50 years.
However, an Indian study [21] demonstrated fairly equal
prevalence in the age group 20–40 and 41–60 years (20.6
and 20.7 %, respectively) and decrement in the subjects
older than 61 years.
The weighted mean prevalence of MS in the countries of
South Asia is presented in Fig. 2.
Prevalence of individual components of MS
Nine studies [12–14, 16–19, 22, 27] provided all individual
components of MS, whereas five [15, 20, 21, 23, 26] provided
some of them, and two [24, 25] provided none. Four studies
[14, 15, 21, 26] analysed individual components ofMS by age
group.
Low HDL cholesterol
Fourteen studies reported the prevalence of low levels of HDL
cholesterol. The weighted mean prevalence was 57.9 %. The
prevalence range was 31.6 % [22] to 79.6 % [26]. In seven
studies [12, 14, 17, 20, 23, 26, 27], low HDL cholesterol was
found in more than half of the study participants. Eleven stud-
ies reported the prevalence by gender which provided weight-
ed mean prevalence of 37.9 % for males and strikingly 68.8 %
for females. All of the studies showed higher prevalence in
females than in males. Four studies presented the prevalence
of low levels of HDL cholesterol with age group. In general,
the prevalence trend was observed to be higher in younger age
groups for both genders. A Pakistani [26] and Indian [21]
study identified a highest prevalence in the youngest age
group (20–40 years). An Indian study [15] reported highest
in the age group of 30–39 years in both genders, whereas
another Indian study [14] reported highest in the age group
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of 30–39 years among females and in 40–49 years among
males. The mean value of HDL cholesterol in males and fe-
males was given in four studies, out of which three [15, 17,
22] documented higher values in females, one [16] reported
higher in males, one [26] showed similar value in both.
Hypertriglyceridemia
The weighted mean prevalence of hypertriglyceridemia was
37.2 %. Thirteen studies included the prevalence of high
levels of triglycerides in the range varying from 25.2 % [12]
Table 1 The weighted mean
prevalence of metabolic
syndrome and individual
components
Variables Male (%) Female (%) Total (%) Range (%)
MS definition
ATP III 22.1 29.5 26.1 18.3–35.8
IDF 18.8 34.3 29.8 11.2–40.0
Modified ATPIII 28.8 35.8 32.5 19.5–46.1
WHO 15.6 12.8 14.0 8.6–23.2
Individual MS components
Low HDL-C 37.9 68.8 57.9 31.6–79.6
Hypertriglyceridemia 37.2 36.1 37.2 25.2–55.1
Hyperglycaemia 27.9 27.6 28.9 9.2–65.1
Hypertension 42.3 38.1 48.5 21.2–81.1
Adbominal obesity 11.2 29.8 23.4 10.0–70.9
Abdominal obesity (South Asian cut-off) 37.9 47.9 43.2 21.6–60.3
Fig. 2 The weighted mean
prevalence of metabolic
syndrome by country of South
Asia
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to 55.1 % [23]. The weighted mean prevalence was margin-
ally higher in males (37.2 %) than that in females (36.1 %).
Eleven studies provided the prevalence of hypertriglyc-
eridemia by gender; however, only three studies [19, 20, 26]
showed higher prevalence of triglyceride in females. Accord-
ing to age groups, hypertriglyceridemia was mostly observed
among participants in middle age of 40–60 years for both
genders.
Hyperglycaemia
The prevalence of hyperglycaemia was given in 11 studies.
The weighted mean prevalence was 28.9 %, and the preva-
lence range was between 9.2 % [17] and 65.1 % [22]. Ten
studies described the prevalence by gender which demonstrat-
ed that males and females had fairly equal weighted mean
prevalence (males 27.9 % vs females 27.6 %). While consid-
ering individual studies, only three [18, 19, 26] reported
higher prevalence in females. For both genders, increased
prevalence of hyperglycaemia was observed with increasing
age.
Hypertension
Nine studies provided the prevalence of hypertension with the
weighted mean prevalence of 48.5 %. This prevalence varied
from 21.2 % [13] to 81.1 % [23]. Males had higher weighted
mean prevalence of hypertension compared to females (males,
42.3 %; females, 38.1 %). Among the eight studies which
showed gender wise prevalence, only two studies [17, 22]
reported slightly higher prevalence in females than that in
males. Hypertension was found increase along with increasing
age for both genders.
Abdominal obesity
The prevalence of abdominal obesity was presented in 11
studies. Not considering the South Asian cut-off point, the
weighted mean prevalence was 23.4 %, in the range of
10.0 % [27] to 70.9 % [21]. Females had nearly three times
higher weighted mean prevalence than males (females,
29.8 %; males, 11.2 %). Gender wise prevalence was shown
in six studies, and females had decidedly greater prevalence in
all of these. The difference in the prevalence was at least 9.5 %
[17] and 29.3 % [19] in maximum.
Moreover, the weighted mean prevalence of abdominal
obesity increased sharply to 43.2 % while considering the
South Asian cut-off point for waist circumference (male,
≥90 cm; female, ≥80 cm) [33]. Six studies [13, 16–19, 22]
presented abdominal obesity with the South Asian cut-off
point. According to this cut-off, females had considerably
higher weighted mean prevalence (females 47.9 % vs males
37.9 %). Similarly, by age group, abdominal obesity was
observed highly prevalent among middle age (40–60 years)
participants for both genders. Six studies reported the mean
value of WC by gender, of which five [13, 15–17, 22] noted
higher mean value in males, but one [26] showed higher in
females.
Urban and rural difference
The weighted mean prevalence of MS in urban areas was
higher than in the rural areas by all definitions except WHO
(ATPIII, 28.7 vs 21.6 %; modified ATPIII, 38.8 vs 11.7 %;
IDF, 34.1 vs 19.2 %; and WHO, 23.2 vs 30.7 %). The
difference was more striking in modified ATPIII criteria. In
both settings, females had usually higher weighted mean
prevalence of MS than in males. Table 2 shows the weighted
mean prevalence of MS by urban and rural setting for both
genders.
Discussion
The findings of this review suggest that more than one quarter
of the participants had MS, with more propensity in females.
South Asians residing in urban areas had markedly higher
prevalence of MS, in both genders. Low levels of HDL-
cholesterol were found in nearly 70 % of females and were
more prevalent in young people of both genders. Another
striking finding was that hypertension was observed in nearly
half of the participants and central obesity in more than one
third. Further, we found that males were more likely to have
increased levels of hypertension, whereas females were
Table 2 The weighted mean prevalence of metabolic syndrome in
urban and rural setting
MS definitions Male (%) Female (%) Total (%)
ATPIII
Urban 23.9 33.2 28.7
Rural 16.7 24.8 21.6
Modified ATPIII
Urban 34.6 42.9 38.8
Rural 11.9 11.6 11.7
IDF
Urban 25.8 41.1 34.1
Rural 10.4 24.7 19.2
WHO
Urban 27.3 19.7 23.2
Rural 30.0 31.1 30.7
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comparatively more likely to have low levels of HDL-
cholesterol and central obesity.
Our findings indicate that the prevalence of MS in South
Asia stands neither in a lower position nor in a higher position
across the globe, while comparing it with the systematic re-
views or best available studies from other parts of the world.
Our findings are fairly similar to the results of systematic
reviews of Latin American countries [24.9 % (ATP III)] [6],
a nationally representative study of Australia [22.1 % (ATP
III), 30.7 % (IDF)] [34] and combined prospective studies of
Europe [15 % (WHO)] [35]. In contrast, our study reported
distinctly higher prevalence than in the African studies (0 to
7.9 % by any definitions) [36, 37], and a nationally represen-
tative study of Eastern Asia (China) [13.7 % (ATP III)] [38].
However, our figure is lower than the prevalence identified in
a national survey of America [35 % (ATP III), 39 % (IDF)] [5]
and in a systematic review of the Gulf countries [20.7–37.2 %
(ATP III), 29.6–36.2 % (IDF)] [7].
This study demonstrated low HDL cholesterol as the most
frequent individual component of MS with weighted mean
prevalence of 57.9 %, and considerably higher among the
females. A Latin American systematic review [6] also
displayed highest prevalence of low HDL cholesterol
(62.9 %), and also at greater proportion among the females,
but the gender difference was much wider in our finding.
Hypertension was shown to be the most prominent MS com-
ponent in Europe (63.5 %) [35] and in Eastern Asia (41.2 %)
[38]. Central obesity, which was the third most prevalent MS
component in our study (44.5 %), was the most prevalent one
in the USA (38.6 %) [5] and in Africa [37].
The underlying factors behind the high prevalence of dys-
lipidemia, hypertension and central obesity among South
Asians could be multifarious. However, an increasing trend
of urbanization and predilection towards ‘westernized’ life-
style are mainly implicated [39–41], which could influence
glucose intolerance, abdominal obesity and dyslipidemia.
Misra et al. [42] suggested the possible role of body compo-
sition in the genesis of atherogenic dyslipidemia among South
Asians. They argued that a higher percentage of body fat,
excess truncal fat and increased intra-abdominal fat accumu-
lation may be linked with insulin resistance and consequent
dyslipidemia. Moreover, the INTERHEART study also found
lower prevalence of protective factors in South Asian controls
compared with controls from other countries (moderate or
high intensity exercise, 6.1 vs 21.6 %; daily intake of fruits
and vegetables, 26.5 vs 45.2 %) [10].
Some of the studies showed a genetic susceptibility of
South Asians to central obesity and MS [43], low levels of
HDL-cholesterol [44] and serum lipids and obesity [45].
Moreover, some genetically based hypotheses have also been
postulated which may explain South Asians propensity to
central obesity, namely ‘the thrifty genotype’ [46], ‘the thrifty
phenotype’ [47], ‘adipose tissue compartment overflow
hypothesis’ [48], ‘variable disease selection hypothesis’ [49]
and ‘the mitochondrial efficiency hypothesis’ [50]. The vast
majority of these genetic studies were limited to Indians and
migrant Indian populations. In addition, the prevalence of MS
among migrant South Asians living in western countries was
also higher when compared with multiple ethnic group popu-
lations [51, 52] which suggests that modifiable correlates of
MS may not be solely responsible for its increasing rates.
In this study, higher prevalence of MS in females was
found compared tomales. This finding can be partly explained
by the explanation that culturally South Asian females are
mostly engaged in the household tasks and have a more sed-
entary lifestyle than males. South Asian women also have
poor access to the health services resulting in both late diag-
nosis and poor management of the disease [53].
Limitations of this review included not being able to search
grey literature, only considering articles published in English
language on or beyond the year 2000, and heterogeneity in the
methodological quality of the studies (mainly discrepancies in
measuring waist circumference and some variations in the cut-
off value). Similarly, we could not rule out the possible bias
due to the disproportionately higher representation of Indian
studies. The main strength of this review is that we explored
three major medical databases PubMed, OvidSP (MedLine
and EMBASE) and Scopus. Also, we considered the most
common definitions of MS.
Conclusion
South Asian countries have witnessed increasing burden of
risk factors and diseases related with metabolic root. Nonethe-
less, they are grappling with limited health care resources and
capacity. The actual burden of MS in South Asia is still ob-
scure because none of the South Asian countries have nation-
ally representative studies. The research environment should
be consolidated, and research capacity should be strength-
ened. This systematic review suggests that MS is very com-
mon in this region and deserves urgent attention from both the
clinical and public health viewpoint. Along with affordable
and increased access to medical treatment, an intensified ap-
proach on primordial and primary prevention of metabolic
disorders should be the utmost priority for South Asian coun-
tries, with special attention to females. Finally, heterogeneity
of included studies limits our ability to conduct a meta-analy-
sis. This needs to be addressed in the future.
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